TRMEDO Stock Overview
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Thor Medical ASA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr1.56 |
52 Week High | kr0 |
52 Week Low | kr0 |
Beta | 0 |
1 Month Change | 0% |
3 Month Change | -3.70% |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 11.17% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
TRMEDO | GB Biotechs | GB Market | |
---|---|---|---|
7D | 0% | 3.8% | 2.0% |
1Y | n/a | -23.3% | 4.5% |
Return vs Industry: Insufficient data to determine how TRMEDO performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how TRMEDO performed against the UK Market.
Price Volatility
TRMEDO volatility | |
---|---|
TRMEDO Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 8.3% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.4% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: TRMEDO has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine TRMEDO's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | n/a | Alf Bjørseth | www.thormedical.no |
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. The company was founded in 2017 and is headquartered in Oslo, Norway.
Thor Medical ASA Fundamentals Summary
TRMEDO fundamental statistics | |
---|---|
Market cap | kr213.69m |
Earnings (TTM) | -kr5.60m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-38.2x
P/E RatioIs TRMEDO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TRMEDO income statement (TTM) | |
---|---|
Revenue | kr0 |
Cost of Revenue | kr0 |
Gross Profit | kr0 |
Other Expenses | kr5.60m |
Earnings | -kr5.60m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 30, 2024
Earnings per share (EPS) | -0.024 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did TRMEDO perform over the long term?
See historical performance and comparison